G. Höffken Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France D.

L. S. Tzouvelekis, A. Markogiannakis, E. Piperaki, M. Souli, G. L

Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods A. Ducournau, L. Bénéjat, E. Sifré, E. Bessède,

L. Boyanova Clinical Microbiology and Infection

Benchmarking inappropriate empirical antibiotic treatment

Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study S. Rhedin, I. Galanis, F. Granath,

G. Cornaglia, A. Lönnroth, M. Struelens

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis G. Choudhury,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

A.K. Reddy, P. Garg, I. Kaur Clinical Microbiology and Infection

M. Giannella, B. Pinilla, J. A. Capdevila, J. Martínez Alarcón, P

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Non-antibiotic strategies for sepsis

Clinical Microbiology and Infection

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients?

Impact of antibiotic restrictions: the pharmaceutical perspective

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Sofie Arens, Jan Verhaegen, Ludo Verbist

Training for the infectious diseases speciality in Norway

Community-acquired pneumonia: the evolving challenge

Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands

Laboratory diagnosis and biosafety issues of biological warfare agents

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Metagenomics and probiotics

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases L. Romero, L. López,

Community-acquired pneumonia: epidemiologic and clinical consideration

M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi

Benchmarking inappropriate empirical antibiotic treatment

Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study S. Rhedin, I. Galanis, F. Granath,

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Clinical infection services—the Leiden experience

An after-hours clinical liaison blood culture service—is it worth it?

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

W. Eugene Sanders, Christine C. Sanders

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Community-acquired acute bacterial meningitis in the elderly in Turkey

Impact of antibiotic restrictions: the patient's perspective

J. Segreti Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Presentation transcript:

Is the use of narrow-spectrum antibiotics too narrow-minded in the treatment of severe infections? G. Höffken Clinical Microbiology and Infection Volume 6, Pages 7-10 (August 2000) DOI: 10.1046/j.1469-0691.2000.00003.x Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 1 Reasons for modifying empirical therapy in episodes of ICU-acquired pneumonia (data from [11]). A total of 249 reasons were given for 214 episodes. Clinical Microbiology and Infection 2000 6, 7-10DOI: (10.1046/j.1469-0691.2000.00003.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 2 Reasons for modifying empirical therapy in episodes of ICU-acquired pneumonia by the treatment regimen administered (data from [11]). Monotherapy, 59 reasons were given for 50 episodes; two antibiotics, 164 reasons were given for 139 episodes; three antibiotics, 26 reasons were given for 25 episodes. Clinical Microbiology and Infection 2000 6, 7-10DOI: (10.1046/j.1469-0691.2000.00003.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 3 Mortality rates in patients with ventilator-acquired pneumonia when treated initially with adequate or inadequate therapy (data from [12] and [13]). Clinical Microbiology and Infection 2000 6, 7-10DOI: (10.1046/j.1469-0691.2000.00003.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 4 Proportion of clinical bacterial isolates (n > 12 000) susceptible to a selection of antibiotic agents in current clinical use (data from [15]). Clinical Microbiology and Infection 2000 6, 7-10DOI: (10.1046/j.1469-0691.2000.00003.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions